Jointown Pharmaceutical Group Co., Ltd (SHA:600998)
China flag China · Delayed Price · Currency is CNY
5.22
-0.05 (-0.95%)
At close: Feb 6, 2026

SHA:600998 Income Statement

Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2024FY 2023FY 2022FY 2021FY 2020
Period Ending
Sep '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20
Operating Revenue
157,592151,695149,981140,282122,359110,819
Other Revenue
115.13115.13158.54142.1648.0940.49
157,707151,810150,140140,424122,407110,860
Revenue Growth (YoY)
5.70%1.11%6.92%14.72%10.42%11.42%
Cost of Revenue
145,744140,075138,140129,560112,636100,981
Gross Profit
11,96411,73512,00010,8649,7729,879
Selling, General & Admin
7,7297,2297,1936,6376,0975,667
Research & Development
146.31146.7196.61178.39194.94126.63
Other Operating Expenses
430.86413.12425.6598.16293.01253.25
Operating Expenses
8,4467,8137,9477,0746,6846,155
Operating Income
3,5183,9234,0533,7903,0873,724
Interest Expense
-1,057-1,284-1,318-1,221-1,145-1,027
Interest & Investment Income
2,2501,456255.17490.63310.74288.54
Currency Exchange Gain (Loss)
-0.81-0.81-4.34-17.05-6.65-1.53
Other Non Operating Income (Expenses)
-135.94-138.58-265.43-281.66-151.72-155.5
EBT Excluding Unusual Items
4,5743,9552,7212,7602,0942,828
Impairment of Goodwill
-10.85-10.85-1.18---
Gain (Loss) on Sale of Investments
-26.16-98.35-78.41.441,2351,052
Gain (Loss) on Sale of Assets
-675.16-425.835.1145.676.72258.03
Asset Writedown
-28.39----2.35-0.69
Other Unusual Items
217.45217.45344.6230.929.12196.12
Pretax Income
4,0513,6372,9912,8383,3634,334
Income Tax Expense
958.57851.03701.2552.55754.88948.94
Earnings From Continuing Operations
3,0932,7862,2902,2862,6083,385
Minority Interest in Earnings
-305.97-279.05-115.62-200.57-160.05-310.03
Net Income
2,7872,5072,1742,0852,4483,075
Net Income to Common
2,7872,5072,1742,0852,4483,075
Net Income Growth
36.16%15.33%4.27%-14.84%-20.38%78.10%
Shares Outstanding (Basic)
5,0725,0155,0565,2745,1875,172
Shares Outstanding (Diluted)
5,0725,0155,0565,2745,1875,339
Shares Change (YoY)
1.48%-0.81%-4.14%1.68%-2.84%-3.46%
EPS (Basic)
0.550.500.430.400.470.59
EPS (Diluted)
0.550.500.430.400.470.58
EPS Growth
34.18%16.28%8.78%-16.25%-18.06%84.50%
Free Cash Flow
2,0542,1073,6992,7432,0731,987
Free Cash Flow Per Share
0.410.420.730.520.400.37
Dividend Per Share
0.2000.2000.1940.1860.1120.186
Dividend Growth
3.20%3.20%4.31%66.64%-39.99%-
Gross Margin
7.59%7.73%7.99%7.74%7.98%8.91%
Operating Margin
2.23%2.58%2.70%2.70%2.52%3.36%
Profit Margin
1.77%1.65%1.45%1.49%2.00%2.77%
Free Cash Flow Margin
1.30%1.39%2.46%1.95%1.69%1.79%
EBITDA
4,2174,6124,7304,4163,6344,239
EBITDA Margin
2.67%3.04%3.15%3.15%2.97%3.82%
D&A For EBITDA
699.22689.68676.96626.41547.21514.33
EBIT
3,5183,9234,0533,7903,0873,724
EBIT Margin
2.23%2.58%2.70%2.70%2.52%3.36%
Effective Tax Rate
23.66%23.40%23.45%19.47%22.45%21.89%
Revenue as Reported
157,707151,810150,140140,424122,407110,860
Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.